Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Telaglenastat (CB 839) 是一种选择性可逆的,有口服活性的谷氨酰胺酶 1 (GLS1) 抑制剂,抑制 GLS1剪接变异体 KGA 和 GAC,比 GLS2 具有更高的选择性。它可诱导细胞自噬 ,具有抗肿瘤活性。它对小鼠类肾和脑中的内源性谷氨酰胺酶的 IC50值分别为 23 nM 和 28 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 233 | 现货 | ||
2 mg | ¥ 329 | 现货 | ||
5 mg | ¥ 536 | 现货 | ||
10 mg | ¥ 828 | 现货 | ||
25 mg | ¥ 1,590 | 现货 | ||
50 mg | ¥ 2,490 | 现货 | ||
100 mg | ¥ 3,930 | 现货 | ||
500 mg | ¥ 7,880 | 现货 | ||
1 g | ¥ 9,820 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 659 | 现货 |
产品描述 | Telaglenastat (CB 839) (IC50 of 24 nM), an effective, specific, and oral inhibitor, which is bioavailable glutaminase, for recombinant human GAC. |
靶点活性 | Glutaminase:24 nM |
体外活性 | CB-839 exhibits time-dependent and slowly reversible kinetics. IC50 values for glutaminase inhibition by CB-839 following preincubation with rHu-GAC for-1 hour are < 50 nmol/L, at least 13-fold lower than with BPTES. CB-839 has antiproliferative activity in a triple-negative breast cancer (TNBC) cell line, HCC-1806, while no antiproliferative activity is observed in an estrogen receptor–positive cell line, T47D.[1] |
体内活性 | In the mouse TNBC model, single agent CB-839 (200 mg/kg, p.o.) suppresses tumor growth by 61% relative to vehicle control. In the mouse JIMT-1 xenograft model, CB-839 alone (200 mg/kg, p.o.) results in 54% tumor growth inhibition (TGI) relative to vehicle control, combination of CB-839 (200 mg/kg, p.o.) with paclitaxel (10 mg/kg, p.o.) largely suppresses the regrowth of the tumors resulting in a TGI relative to vehicle control of 100%.[1] |
激酶实验 | Inhibition of CB-839 on rHu-GAC: The enzymatic activity is measured in assay buffer containing 50 mM Tris-Acetate pH 8.6, 150 mM K2HPO4 , 0.25 mM EDTA, 0.1 mg/mL bovine serum albumin, 1 mM DTT, 2 mM NADP+ and 0.01% Triton X-100. To measure inhibition, the inhibitor (prepared in DMSO) is first pre-mixed with glutamine and glutamate dehydrogenase (GDH) and reactions are initiated by the addition of rHu-GAC. Final reactions contains 2 nM rHu-GAC, 10 mM glutamine, 6 units/mL GDH and 2% DMSO. Generation of NADPH is monitored by fluorescence (Ex340/Em460 nm) every minute for 15 minutes on a SpectraMax M5e plate reader. Relative fluorescence units (RFU) are converted to units of NADPH concentration (μM) using a standard curve of NADPH. Each assay plate incorporates control reactions that monitores the conversion of glutamate (1 to 75 μM) plus NADP+ to α-ketoglutarate plus NADPH by GDH. Under these assay conditions, up to 75 μM glutamate is stoichiometrically converts to α-ketoglutarate/NADPH by GDH. Initial reaction velocities are calculated by fitting the first 5 minutes of each progress curve to a straight line. Inhibition curves are fitted to a four-parameter dose response equation of the form: % activity = Bottom + (Top-Bottom)/(1+10^((LogIC50-X)*HillSlope)). |
细胞实验 | For viability assays, all cell lines are treated with CB-839 at the indicated concentrations for 72 hours and analyzed for antiproliferative effects using Cell Titer Glo.(Only for Reference) |
别名 | CB 839, CB839, CB-839 |
分子量 | 571.57 |
分子式 | C26H24F3N7O3S |
CAS No. | 1439399-58-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: < 1 mg/mL (insoluble or slightly soluble)
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 93 mg/mL (162.7 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.7496 mL | 8.7478 mL | 17.4957 mL | 43.7392 mL |
5 mM | 0.3499 mL | 1.7496 mL | 3.4991 mL | 8.7478 mL | |
10 mM | 0.175 mL | 0.8748 mL | 1.7496 mL | 4.3739 mL | |
20 mM | 0.0875 mL | 0.4374 mL | 0.8748 mL | 2.187 mL | |
50 mM | 0.035 mL | 0.175 mL | 0.3499 mL | 0.8748 mL | |
100 mM | 0.0175 mL | 0.0875 mL | 0.175 mL | 0.4374 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Telaglenastat 1439399-58-2 Autophagy Metabolism Proteases/Proteasome transporter Glutaminase CB 839 antiproliferative HCC-1806 TNBC breast Inhibitor splice cell PDAC CB839 variants selective cancer triple-negative CB-839 inhibit inhibitor